Primer: Shanghai Junshi Biosciences (688180 CH) - May 2026
Shanghai Junshi Biosciences is an innovation-centric biopharmaceutical firm poised for significant growth, driven by its flagship PD-1...
169 Views
APAC Healthcare Weekly (August 23) – Henlius Bio, Wuxi XDC, Chugai Pharma, Daiichi Sankyo, Celltrion
Henlius strikes biosimilar commercialization deal with Sandoz. Chugai signs exclusive license deal with GSK for anti-dengue virus antibody....
100 Views
APAC Healthcare Weekly (May 31) – Innovent Biologics, Junshi Bio, Henlius Bio, Olympus, GC Bio
Innovent stuck $10.5B outlicensing deal with Pfizer. Olympus will acquire BioProtect. Eli Lilly is acquiring GC Bio’s US affiliate. Dong-A’s...
159 Views
APAC Healthcare Weekly (May 24)– Hansoh, Junshi Bio, Daiichi Sankyo, SanBio, Hanmi Pharm, Yuhan Corp
Hansoh’s HS-10504 tablets secured BTD in China. Junshi Bio secured 13th indication approval for toripalimab. Daiichi Sanyo’s Enhertu and Datroway...
132 Views
Shanghai Junshi Bioscience (1877 HK): Turns Profitable in 1H26 on Steady Domestic Revenue of Tuoyi
Junshi Bioscience reports maiden net profit in 1H26. Steady sales growth of toripalimab led to breakthroughs in revenue and profit. Continued...
95 Views